Selective recognition and elimination of nicotinic acetylcholine receptor-reactive B cells by a recombinant fusion protein AChR-Fc in myasthenia gravis in vitro

Journal of Neuroimmunology

Volumn 227, Issue 1-2, 2010, Pages 35-43

  Chang, Ting ^a   Lin, Hong ^a   Gao, Jie ^a   Li, Wei ^b   Xu, Jiang ^a   Sun, Chen Jing ^a   Li, Hang ^b   Li, Fan Fan ^b   Song, Yue ^b   Ye, Jing ^b   Li, Zhu Yi ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Autoantibodies; Autoimmunity; Fusion protein; Myasthenia gravis

Indexed keywords

AUTOANTIGEN; B LYMPHOCYTE RECEPTOR; COMPLEMENT; FC RECEPTOR IIB; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN HEAVY CHAIN; NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA1 SUBUNIT FC FUSION PROTEIN; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA1 SUBUNIT; UNCLASSIFIED DRUG; FC RECEPTOR; FCGR2B PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CD19+ B CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURFACE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CROSS LINKING; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG TARGETING; EFFECTOR CELL; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HYBRIDOMA CELL CULTURE; IMMUNIZATION; IN VITRO STUDY; LEWIS RAT; LYMPHOCYTE COUNT; LYMPHOCYTOTOXICITY; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RAT; SPLEEN; SPLEEN CELL; ANIMAL; COMPARATIVE STUDY; GENETICS; GUINEA PIG; HYBRIDOMA; IMMUNOLOGY; LYMPHOCYTE DEPLETION; METABOLISM; PATHOLOGY; PROCEDURES; SYNTHESIS; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANIMALS; B-LYMPHOCYTE SUBSETS; CELL LINE, TUMOR; FEMALE; GUINEA PIGS; HUMANS; HYBRIDOMAS; LYMPHOCYTE DEPLETION; MYASTHENIA GRAVIS; RATS; RATS, INBRED LEW; RECEPTORS, IGG; RECEPTORS, NICOTINIC; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 77956635497     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.06.006     Document Type: Article

References (28)

1. Baek W.S., Bashey A., Sheean G.L. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 2007, 78:771.
2. Baerenwaldt A., Nimmerjahn F. Immune regulation: FcgammaRIIB-regulating the balance between protective and autoreactive immune responses. Immunol. Cell Biol. 2008, 86:482-484.
3. Bournia V.K., Vlachoyiannopoulos P.G., Selmi C., Moutsopoulos H.M., Gershwin M.E. Recent advances in the treatment of systemic sclerosis. Clin. Rev. Allergy Immunol. 2009, 36:176-200.
4. Dalakas M.C. B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. Pharmacol. Ther. 2006, 112:57-70.
5. Dorner T., Burmester G.R. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr. Opin. Rheumatol. 2003, 15:246-252.
6. Edwards J.C., Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 2006, 6:394-403.
7. Eisenberg R., Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 2006, 2:20-27.
8. Evoli A., Bianchi M.R., Riso R., Minicuci G.M., Batocchi A.P., Servidei S., Scuderi F., Bartoccioni E. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann. NY Acad. Sci. 2008, 1132:76-83.
9. Fukuyama H., Nimmerjahn F., Ravetch J.V. The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+anti-DNA plasma cells. Nat. Immunol. 2005, 6:99-106.
10. Garcia-Carrasco M., Jimenez-Hernandez M., Escarcega R.O., Mendoza-Pinto C., Galarza-Maldonado C., Sandoval-Cruz M., Zamudio-Huerta L., Lopez-Colombo A., Cervera R. Use of rituximab in patients with systemic lupus erythematosus: an update. Autoimmun. Rev. 2009, 8:343-348.
11. Hain B., Jordan K., Deschauer M., Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 2006, 33:575-580.
12. Illa I., Diaz-Manera J., Rojas-Garcia R., Pradas J., Rey A., Blesa R., Juarez C., Gallardo E. Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients. J. Neuroimmunol. 2008, 201-202:90-94.
13. Kerkeni S., Marotte H., Miossec P. Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis. Muscle Nerve 2008, 38:1343-1345.
14. Li J., Tuzun E., Wu X.R., Qi H.B., Allman W., Saini S.S., Christadoss P. Inhibitory IgG receptor FcgammaRIIB fails to inhibit experimental autoimmune myasthenia gravis pathogenesis. J. Neuroimmunol. 2008, 194:44-53.
15. Mihaylova N., Voynova E., Tchorbanov A., Nikolova M., Michova A., Todorov T., Srebreva L., Taskov H., Vassilev T. Selective silencing of disease-associated B-lymphocytes by chimeric molecules targeting their Fc gamma IIb receptor. Int. Immunol. 2008, 20:165-175.
16. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008, 8:34-47.
17. Proby C.M., Ota T., Suzuki H., Koyasu S., Gamou S., Shimizu N., Wahl J.K., Wheelock M.J., Nishikawa T., Amagai M. Development of chimeric molecules for recognition and targeting of antigen-specific B cells in pemphigus vulgaris. Br. J. Dermatol. 2000, 142:321-330.
18. Reiners K.S., Hansen H.P., Krussmann A., Schon G., Csernok E., Gross W.L., Engert A., Von Strandmann E.P. Selective killing of B-cell hybridomas targeting proteinase 3, Wegener's autoantigen. Immunology 2004, 112:228-236.
19. Sabahi R., Anolik J.H. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 2006, 66:1933-1948.
20. Tchorbanov A.I., Voynova E.N., Mihaylova N.M., Todorov T.A., Nikolova M., Yomtova V.M., Chiang B.L., Vassilev T.L. Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice. Eur. J. Immunol. 2007, 37:3587-3596.
21. Thakre M., Inshasi J., Marashi M. Rituximab in refractory MuSK antibody myasthenia gravis. J. Neurol. 2007, 254:968-969.
22. Tzartos S.J., Seybold M.E., Lindstrom J.M. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc. Natl. Acad. Sci. USA 1982, 79:188-192.
23. Tzartos S.J., Sophianos D., Efthimiadis A. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera. J. Immunol. 1985, 134:2343-2349.
24. Wu B., Goluszko E., Christadoss P. Experimental autoimmune myasthenia gravis in the mouse. Curr. Protoc. Immunol. 2001, 18. (Chapter 15, Unit 15).
25. Wylam M.E., Anderson P.M., Kuntz N.L., Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J. Pediatr. 2003, 143:674-677.
26. Zaja F., Russo D., Fuga G., Perella G., Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000, 55:1062-1063.
27. Zhu D., Kepley C.L., Zhang M., Zhang K., Saxon A. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat. Med. 2002, 8:518-521.
28. Zhu D., Kepley C.L., Zhang M., Zhang K., Saxon A. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat. Med. 2005, 11:446-449.